Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: galanis e. Cancer Gene Ther. 2022 Mar;29(3-4):369-382. doi: 10.1038/s41417-021-00317-5. Epub 2021 Mar 22. Cancer Gene Ther. 2022. PMID: 33753870 Clinical Trial.
Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
Myers R, Harvey M, Kaufmann TJ, Greiner SM, Krempski JW, Raffel C, Shelton SE, Soeffker D, Zollman P, Federspiel MJ, Blanco M, Galanis E. Myers R, et al. Among authors: galanis e. Hum Gene Ther. 2008 Jul;19(7):690-8. doi: 10.1089/hum.2008.035. Hum Gene Ther. 2008. PMID: 18576918 Free PMC article.
., Teneyck, C.J., Mishra, P.K., Macura, S.I., Russell, S.J., Galanis, E.C. (2003). Cancer. Res. 63, 2462-2469]. MV-CEA is an Edmonston vaccine lineage measles virus strain engineered to express the marker peptide carcinoembryonic antigen (CEA): CEA levels can serve …
., Teneyck, C.J., Mishra, P.K., Macura, S.I., Russell, S.J., Galanis, E.C. (2003). Cancer. Res. 63, 2462-2469]. MV-CEA is an E …
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN. Schiff D, et al. Among authors: galanis e. Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3. Cancer. 2018. PMID: 29313954 Free PMC article. Clinical Trial.
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. Galanis E, et al. Cancer. 2019 Nov 1;125(21):3790-3800. doi: 10.1002/cncr.32340. Epub 2019 Jul 10. Cancer. 2019. PMID: 31290996 Free PMC article. Clinical Trial.
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: galanis e. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: galanis e. Gynecol Oncol. 2023 Feb;169:173. doi: 10.1016/j.ygyno.2022.11.010. Epub 2022 Nov 28. Gynecol Oncol. 2023. PMID: 36456375 No abstract available.
Phase II trial of gemcitabine in advanced sarcomas.
Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Okuno S, et al. Among authors: galanis e. Cancer. 2002 Jun 15;94(12):3225-9. doi: 10.1002/cncr.10602. Cancer. 2002. PMID: 12115355 Free article. Clinical Trial.
Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J. Galanis E, et al. Cancer. 2004 Dec 1;101(11):2557-66. doi: 10.1002/cncr.20653. Cancer. 2004. PMID: 15517589 Free article. Clinical Trial.
347 results